Abstract
It is well established that immunoreactive somatostatin (IRS) is distributed widely in the extrahypothalamic tissues and organs including the pancreas and gastrointestinal tracts Hokfelt et al., 1975) . Immunohistochemical studies clearly demonstrated that IRS existed in D-cells of the islets of Langerhans (Dubois, 1975) . Exogenously administered somatostatin inhibits the release of insulin (IRI) (Alberti et al., 1973) and glucagon (IRG) (Koerker et al., 1974) . On the other hand, glucose (Schauder et al., 1976 (Schauder et al., , 1977 Ipp et al., 1977a) amino acids (Ipp et al., 1977a), tolbutamide (Ipp et al., 1977a ) and gastrointestinal hormones (Ipp et al., 1977a, b) have been reported to stimulate the release of endogenous IRS from isolated perfused pancreas, or from isolated perifused pancreatic islets. These observations led to a postulation that IRS in D-cells of the islets may play a physiological role on the regulation of pancreatic endocrine functions (Unger, 1977) . In the islets of diabetic rats and humans, the hypertrophy and hyperplasia of D-cells are observed . These morphological changes are associated with an increase in somatostatin content in the D-cells (Patel and Weir, 1976 the diabetic group were significantly higher than those of the control group (p<0 .001).
When the glucose concentration in the medium was decreased to 2.8 mM IRS levels rose transiently in both groups (Fig  3. lower panel) . The biphasic IRI release was observed with 16.7 mM glucose in the control group, while the secretion of IRI was negligible in the diabetic group (Fig 3. middle panel) . On the other hand, IRG release was suppressed in both groups during the perifusion with 16.7 mM glucose, and the value returned to each baseline level when the glucose concentration of the medium was decreased form 16.7 mM to 2.8 mM (Fig 3.  upper 
Discussion
IRG has been located in the D-cells in the pancreas and gastrointestinal tracts (Hokfelt et al., 1975; Dubois, 1975) . Considering such localization of somatostatin and its pharmacological action in inhibiting pancreatic and gastrointestinal hormones, it is strongly felt that somatostatin regulates the hormone release from the adjacent endocrine cells as a local hormone and plays an important physiological role on the glucose and nutrient homeostasis. In order to prove this theory, many investigations have focused on the relationship among A-, B-and D-cells in the pancreatic islets which is postulated as the "paracrine" hypothesis (Unger, 1977) . According to the "paracrine" hypothesis, one of the three secretory products of these three cell types influences the hormonal secretion from its neighboring cells. The abnormal A-, B-and D-cell functions could explain many abnormal pancreatic endocrine states seen in diabetes . However secretory dynamics of somatostatin from D-cells of diabetic islets remains obscure.
In the present study, we found out that basal levels of IRS in the effluent of diabetic islets were three times as high as those of normal ones and that IRS responded remarkably to the high concentration of glucose and tolbutamide. These results would reflect the hypertrophy and hyDerplasia of D-celis observed in the diabetic rats . Such pathological changes in D-cells in the islets might be caused by the prolonged hyperglycemic stimulation secondary to diabetes or by the direct effect of STZ on D-cells.
In our perifusion system IRS was increased 58 min after exposure to the high concentration of glucose in normal islets. This delayed response was different from the results reported by Ipp et al. (1977) and Schauder et al. (1977) , who found an immediate elevation of IRS levels after the high concentration of glucose. On the other hand, Barden et al. (1976) and Weir et al. (1979) did not observe any increase in IRS release following 300 mg/100 ml glucose. The different assay system and the different dose of glucose utilized might account for such discrepancies. The delayed response of IRS to high concentration of glucose was similarly observed in the diabetic group on our study. The significance of such responses to glucose in normal and diabetic islets remains unclear.
It is of interest to note that despite an increase in somatostatin levels in the diabetic islets, glucagon release was twice as high as the normal level. If somatostatin had inhibited glucagon secretion as a local hormone, the glucagon level would be lower in the effluent of the diabetic group than in the control group. Otherwise, D-cells would secrete a large amount of somatostatin in order to restore excessive glucagon secretion in diabetes millitus as described by Buchanan et al. (1973) and Weir et al. (1976) .
In the present study, both somatostatin and glucagon were released transiently from islets in respone to an abrupt fall in the glucose concentration from 16.7 mM to 2.8 mM. A possible role of this somatostatin secretion may be related to the prevention of endogenous insulin overshoot in order to avoid further hypoglycemia. It could be also explained by the fact that increased glucagon release in response to hypogly- IRS SECRETION  FROM  DIABETIC  ISLETS  695 cemia (Patton et al., 1977; Unger et al., 1962) had a stimulatory effect on 1-cells within the islets. This may cause a transient increase in somatostatin secretion, since a high concentration of exogenous and presumably endogenous glucagon (Patton et al., 1976) stimulated the release of somatostatin from rat pancreas. Also noteworthy is the present finding that the D-ceils in STZ diabetic islets which secreted little endogenous insulin responded in a normal fashion to glucose and tolbutamide.
In other words, glucose-and tolbutamide-induced endogenous insulin did not exert a stimulatory action on somatostatin release in normal islets through the "paracrine" mechanism . Patton et al. (1977) showed that exogenous insulin did not augment somatostatin release from dog pancreas.
In the present study we showed the secretory patterns of somatostatin, glucagon and insulin responses to glucose and tolbutamide in normal and diabetic islets. However, it was not possible to obtain direct evidence indicating the possible interaction of the secretion of these three hormones. Further investigation will be necessary to elucidate the "paracrine" regulation of islet hormone secretion.
